The Knowledge Transfer Network’s (KTN) Neurotechnology Special Interest Group (Neurotechnology SIG) will be running a ‘Mood and Psychosis Bio-design workshop’ on 12th Nov, in Nottingham, in collaboration with MindTech.

MindTech is funded by the National Institute of Health Research and is based at the Institute of Mental Health. They focus on many non-drug treatments, known as psychosocial interventions. Areas of interest include: mood disorders, psychosis, dementia and neurodevelopmental disorders such as: Attention Deficit Hyperactivity Disorder (ADHD) and Tourette syndrome.
Dr Michael Craven, Senior Research Fellow, within the University of Nottingham, works fulltime for MindTech. Mike describes their work as “very much a partnership with others in the field to advance the evidence for the right types of solutions, suggested by industry or parts of research”. This can comprise of clinical trials, identifying potential technologies, identifying gaps in the healthcare system and advancing solutions suggested by industry or research.

The mood and psychosis bio-design workshop aims to bring together clinicians, companies, academics, charities and other stakeholders, to accelerate the development of new neurotechnologies to treat mood and psychotic disorders. Mike will be co-hosting at the KTN’s Neurotechnology SIG Mood and Psychotic Disorders Biodesign workshop, in Nottingham, on Tuesday, 12 November.

Register here for the workshop, to find out more about the work done by MindTech and projects by other companies, clinicians and researchers in the field.